Long form collapsin response mediator protein-1 promotes the migration and invasion of osteosarcoma cells

Hou,Huige; Chen,Lin; Zha,Zhengang; Cai,Shaohui; Tan,Minghui; Guo,Guoqing; Liu,Ning; She,Guorong; Xun,Songwei

doi:10.3892/ol.2016.4562

Long form collapsin response mediator protein-1 promotes the migration and invasion of osteosarcoma cells

Authors:
- Huige Hou
- Lin Chen
- Zhengang Zha
- Shaohui Cai
- Minghui Tan
- Guoqing Guo
- Ning Liu
- Guorong She
- Songwei Xun
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R. China, College of Pharmacy, Jinan University, Guangzhou, Guangdong 510632, P.R. China, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: May 13, 2016 https://doi.org/10.3892/ol.2016.4562
Pages: 23-28

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been reported that long form collapsin response mediator protein-1 (LCRMP-1) promotes the metastasis of non-small cell lung cancer. Osteosarcoma (OS) is a human cancer with a high potential for metastasis. The present study aimed to investigate the role of LCRMP‑1 in OS metastasis. The expression of LCRMP‑1 in OS specimens and cell lines was evaluated using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blot analysis. Furthermore, the migration and invasion of OS cells with LCRMP‑1‑knockdown was investigated to examine the role of LCRMP‑1 in OS metastasis. In addition, the expression of N‑cadherin and matrix metalloproteinases (MMPs), which are involved in cell migration, was evaluated using RT‑qPCR. Increased expression of LCRMP‑1 was observed in the OS tissues and cell lines, accompanied by the enhanced migration and invasion of the OS cells. LCRMP‑1‑knockdown resulted in a significant decrease in the expression of N‑cadherin and MMPs, as well as inhibition of the migration and invasion of the OS cells. Overexpression of LCRMP-1 promoted OS metastasis. Therefore, LCRMP‑1 may be a promising target for the effective treatment of OS.

View Figures

View References

1	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
2	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
3	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
4	Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
5	Yamashita N, Uchida Y, Ohshima T, Hirai S, Nakamura F, Taniguchi M, Mikoshiba K, Honnorat J, Kolattukudy P, Thomasset N, et al: Collapsin response mediator protein 1 mediates reelin signaling in cortical neuronal migration. J Neurosci. 26:13357–13362. 2006. View Article : Google Scholar : PubMed/NCBI
6	Shih JY, Lee YC, Yang SC, Hong TM, Huang CY and Yang PC: Collapsin response mediator protein-1: A novel invasion-suppressor gene. Clin Exp Metastasis. 20:69–76. 2003. View Article : Google Scholar : PubMed/NCBI
7	Shih JY, Yang SC, Hong TM, Yuan A, Chen JJ, Yu CJ, Chang YL, Lee YC, Peck K, Wu CW and Yang PC: Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst. 93:1392–1400. 2001. View Article : Google Scholar : PubMed/NCBI
8	Pan SH, Chao YC, Chen HY, Hung PF, Lin PY, Lin CW, Chang YL, Wu CT, Lee YC, Yang SC, et al: Long form collapsin response mediator protein-1 (LCRMP-1) expression is associated with clinical outcome and lymph node metastasis in non-small cell lung cancer patients. Lung Cancer. 67:93–100. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pan SH, Chao YC, Hung PF, Chen HY, Yang SC, Chang YL, Wu CT, Chang CC, Wang WL, Chan WK, et al: The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. J Clin Invest. 121:3189–3205. 2011. View Article : Google Scholar : PubMed/NCBI
10	Livak and Schmittgen: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
12	Meyers PA and Gorlick R: Osteosarcoma. Pediatr Clin North Am. 44:973–989. 1997. View Article : Google Scholar : PubMed/NCBI
13	Wang WL, Hong TM, Chang YL, Wu CT, Pan SH and Yang PC: Phosphorylation of LCRMP-1 by GSK3β promotes filopoda formation, migration and invasion abilities in lung cancer cells. PLoS One. 7:e316892012. View Article : Google Scholar : PubMed/NCBI
14	Klein MJ and Siegal GP: Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol. 125:555–581. 2006. View Article : Google Scholar : PubMed/NCBI
15	Harada S, Wei S and Siegal GP: Molecular pathology of osteosarcoma. In: Bone Cancer. Primary Bone Cancers and Bone Metastases. Heymann D: (2nd). Academic Press. (Cambridge, MA). 213–222. 2014.
16	Tirino V, Paino F, Papaccio F, La Noce M, Papaccio G and Desiderio V: Stemness markers of osteosarcoma. In: Bone Cancer. Primary Bone Cancers and Bone Metastases. Heymann D: (2nd). Academic Press. (Cambridge, MA). 205–211. 2014.
17	Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
18	Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
19	Bryan RT and Tselepis C: Cadherin switching and bladder cancer. J Urol. 184:423–431. 2010. View Article : Google Scholar : PubMed/NCBI
20	Patel S, Sumitra G, Koner BC and Saxena A: Role of serum matrix metalloproteinase-2 and −9 to predict breast cancer progression. Clin Biochem. 44:869–872. 2011. View Article : Google Scholar : PubMed/NCBI
21	Walkley CR: Modeling osteosarcoma: In vitro and in vivo approaches. In: Bone Cancer. Primary Bone Cancers and Bone Metastases. Heymann D: (2nd). Academic Press. (Cambridge, MA). 195–204. 2014.